Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Blood blood.2025028313.

https://doi.org/10.1182/blood.2025028313

Published: 2025

Includes: Supplemental data

Journal Articles

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Blood blood.2025029234.

https://doi.org/10.1182/blood.2025029234

Published: 2025

Includes: Supplemental data

Journal Articles

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

Blood (2024) 144 (23): 2432–2438.

https://doi.org/10.1182/blood.2024024995

Published: 2024

Includes: Supplemental data

Journal Articles

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

Blood (2024) 144 (Supplement 1): 670.

https://doi.org/10.1182/blood-2024-194041

Published: 2024

Journal Articles

GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Blood (2024) 144 (Supplement 1): 678.

https://doi.org/10.1182/blood-2024-203170

Published: 2024

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

Blood (2024) 144 (Supplement 1): 889.

https://doi.org/10.1182/blood-2024-202995

Published: 2024

Journal Articles

CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Blood (2024) 144 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2024-207942

Published: 2024

Journal Articles

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Blood (2024) 144 (Supplement 1): 1957.

https://doi.org/10.1182/blood-2024-211383

Published: 2024

Journal Articles

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Blood (2024) 144 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2024-205453

Published: 2024

Journal Articles

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Ricardo Errazquin, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Esther Parra, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Teresa Cedena Romero, Joaquin Martínez-López, Rosa Ayala, Inmaculada Rapado

Blood (2024) 144 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2024-207390

Published: 2024

Journal Articles

Long-Term Effects of Belantamab Mafodotin Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) on T Cell Exhaustion Phenotype

Mauro Lorenzo, Juan-José Garcés, Leire Burgos, Irene Manrique, Marta Lasa, Noemi Puig, Janet Sotolongo-Ravelo, Marta González-Rodríguez, Bárbara Castellanos, Maria Teresa Cedena Romero, Bruno Paiva, Veronica Gonzalez-Calle, Maria-Victoria Mateos, Mercedes Garayoa, Teresa Paíno

Blood (2024) 144 (Supplement 1): 6866.

https://doi.org/10.1182/blood-2024-209686

Published: 2024

Journal Articles

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Blood (2024) 144 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2024-198114

Published: 2024

Journal Articles

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Blood (2024) 144 (Supplement 1): 1879.

https://doi.org/10.1182/blood-2024-201435

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Aintzane Zabaleta, Noemi Puig, Maria Teresa Cedena Romero, Jose J Perez, Cristina Moreno, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Veronica Gonzalez-Calle, Lucia Lopez Corral, Beatriz Rey-Búa, Borja Puertas Martínez, Fatima Miras, Jose Sanchez-Pina, Nieves Lopez, Joaquin Martinez-Lopez, Maria Victoria Mateos, Jesus San-Miguel, Bruno Paiva

Blood (2023) 142 (Supplement 1): 94.

https://doi.org/10.1182/blood-2023-185980

Published: 2023

Journal Articles

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Blood (2023) 142 (18): 1518–1528.

https://doi.org/10.1182/blood.2022019531

Published: 2023

Journal Articles

GEM2017FIT Trial: Induction Therapy with Bortezomib-Melphalan and Prednisone (VMP) Followed By Lenalidomide and Dexamethasone (Rd) Versus Carfilzomib, Lenalidomide and Dexamethasone (KRd) Plus/Minus Daratumumab (D), 18 Cycles, Followed By Consolidation and Maintenance Therapy with Lenalidomide and Daratumumab: Phase III, Multicenter, Randomized Trial for Elderly Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients Aged between 65 and 80 Years

Blood (2023) 142 (Supplement 1): 209.

https://doi.org/10.1182/blood-2023-179866

Published: 2023

Journal Articles

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Blood (2023) 142 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2023-179452

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Irene Zamanillo, Santiago Barrio, Alejandro Martín-Muñoz, Sara Dorado, Ana K Ballesteros, Yanira Ruiz-Heredia, Margarita Rodriguez, Carolina Martinez-Laperche, Sandra Martín, Blanca Ferrer Lores, Ivan Martin Castillo, Inmaculada Rapado, Rosa Ayala, Joaquin Martinez-Lopez, Maria Teresa Cedena Romero

Blood (2023) 142 (Supplement 1): 6781.

https://doi.org/10.1182/blood-2023-188600

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial

Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

An IFNγ-Mediated Immune Inflamed Microenvironment State in Multiple Myeloma with TP53 Loss That Can be Therapeutically Exploited

GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation

Clinical Significance of Measurable Residual Disease (MRD) in Light-Chain (AL) Amyloidosis

CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma

Unraveling Long-Term Survival of Multiple Myeloma Patients, the GEM2000 Experience

Survival Improvement of Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma in Two Consecutive Randomized Phase III Trials: Long-Term Follow up of GEM05 and GEM12 Trials

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Long-Term Effects of Belantamab Mafodotin Plus Bortezomib, Lenalidomide and Dexamethasone (VRd) on T Cell Exhaustion Phenotype

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Multiomic Characterization of Clonotypic B Cells in Patients with Monoclonal Gammopathies

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Clinical Significance of Measurable Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Chimeric Antigen Receptor (CAR) T Cells and T-Cell Engagers (TCE)

Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

Sustained Recovery of Uninvolved Heavy/Light Chain Pair Immunoparesis during Maintenance Discriminates Patients with Sustained Negative Minimal Residual Disease

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Parallel Monitoring of Measurable Residual Disease and Chimerism By NGS in Myelodysplastic Syndrome after Allogenic STEM Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only